Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Apply
BDTX-1535
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step